series-a
Stage
1
Investors
About
MetaSight develops liquid biopsy diagnostics using multi-omic mass spectrometry technologies such as metabolomics, lipidomics, and proteomics to enable early detection and monitoring of chronic and acute diseases.
Explore MetaSight's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.